Navigation Links
Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
Date:5/22/2013

NEW ORLEANS, May 22, 2013 /PRNewswire/ -- Hemoglobin A1C levels increased over a four-year period for commercially-insured patients with Type 2 diabetes, while modest improvements in A1C control has been shown to improve health outcomes and can lead to substantial healthcare cost savings, according to two studies presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting.

The two studies, sponsored by Valeritas, makers of the V-Go® insulin delivery device, and conducted in collaboration with HealthCore, a clinical outcomes research company, reviewed data about commercially insured patients being treated for Type 2 diabetes. The first study found that diabetes control, as measured by levels of hemoglobin A1C, worsened among the studied patient population between 2008 and 2011, and the second study suggested that modest improvements in A1C control may lead to substantial cost savings.

Both studies used administrative claims data from the HealthCore Integrated Research DatabaseSM (HIRDSM), associated with a large national health insurer. The studies were jointly designed by Valeritas and HealthCore.

"These studies demonstrate that we, as health professionals, need to help patients better manage their Type 2 diabetes as poor A1C control may have serious human and economic consequences," Matthew Nguyen , PharmD, Vice President, Medical Affairs, Integrated Healthcare Management. "Even modest improvements in hemoglobin A1C levels can have a profound impact on health care spending."

Valeritas sponsored the studies, which underscore the need for innovative approaches to glycemic control. The first study presented at the ISPOR meeting examined medical and pharmacy claims of nearly a quarter of a million individuals for the years 2008 through 2011 who had continuous health plan enrollment
'/>"/>

SOURCE Valeritas, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
2. Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania
3. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
4. Merck and Celebrity Chef Art Smith "Cook Up a Recipe" for Better Type 2 Diabetes Management
5. Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress
6. New Interim Analysis From Observational Study Suggests That Delivery Of Insulin Via Valeritas V-Go Shows Promise In Improving Glycemic Control For Patients With Type 2 Diabetes
7. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
8. Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
9. Judge Nullifies Verdict in Diabetes Drug Case
10. The Importance of Emergency Preparedness: Lilly Diabetes and the American College of Endocrinology (ACE) Help Prep People with Diabetes for Emergencies - Big or Small
11. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Mass. , July 24, 2014   ndd ... function testing (PFT) employing precise ultrasound technology, announced that ... the instrument to measure Carbon Monoxide Diffusing Capacity (DLCO) ... the most comprehensive study of Chronic Obstructive Pulmonary Disease ... cause of death in the U.S. and affects millions ...
(Date:7/23/2014)... N.Y. , July 23, 2014 ... of idelalisib to treat patients with relapsed chronic ... lymphocytic lymphoma (SLL) is a significant advance for ... Idelalisib, which goes by the trade name Zydelig®, ... protein that is highly expressed in many B-cell ...
(Date:7/23/2014)... MOUNTAIN VIEW, Calif. , July 23, 2014 ... translational preclinical research, today unveiled their new logo and ... transformation of Surpass, corporate culture to one where our ... This press release comes on the heels of the ... to the Silicon Valley Team:  David Craig, a veteran ...
Breaking Medicine Technology:EasyOne Pro from ndd Medical Technologies Chosen Again as the Exclusive PFT Testing Technology in Phase 2 of COPDGene Study 2The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... Feb. 15 Intra-Cellular Therapies, Inc. (ITI),announced ... its,first-in-class dual 5HT2A receptor antagonist/dopamine receptor,phosphoprotein modulator ... ITI,s family of compounds that inhibit a ... dysfunction in schizophrenia. Data,characterizing the pharmacological profile ...
... Plan Also Calls for Expansion of Business Development, Streamlining of ... ... Conference Call/Webcast at 11 a.m. EST Today -, LA JOLLA, Calif., ... strategic plan for 2008 with a focus,on clinical development activities to maximize ...
Cached Medicine Technology:Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 2Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 3Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 4TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 2TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 3TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 4TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 5TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 6
(Date:7/24/2014)... July 24, 2014 A new report ... nearly 80 percent of doctors in the U.S. have upgraded ... year. , Doctors appear to be embracing more digital options. ... time, linking them to past patient histories, the latest published ... physician. , A report from the Robert Wood Johnson ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Representatives from ... be on hand to provide educational and support resources ... Meeting next week in Colorado Springs. , The Annual ... of the most renowned neurointerventional research centers ... and innovating together (with or at) symposiums, physician meetings, ...
(Date:7/24/2014)... The Arm Lift, also known as brachioplasty, is ... from the upper arms to create a more toned, slimmed ... can become lax and may begin to sag, resulting in ... appearance of sagging upper arms, and seek treatment to restore ... is now offering brachioplasty to tighten and improve the contours ...
(Date:7/24/2014)... Colo. (PRWEB) July 24, 2014 ... Prepared to Identify and Prevent the Three Infections ... Infections?’ is a go-to guide to help ... risk factors and details basic prevention measures that ... The e-book is available for download at ...
(Date:7/24/2014)... 24, 2014 The Republic of Tea, leading ... CARDAMOM CRÈME BRÛLÉE TEA to celebrate “The Hundred-Foot Journey,” a ... and Juliet Blake. A hundred-foot journey begins in the moment ... into a new realm that is far out of your ... physical distance that materially changes the course of your life ...
Breaking Medicine News(10 mins):Health News:Doctors Embracing Changing Technologies, And Technology Brings Options to Treatment 2Health News:Doctors Embracing Changing Technologies, And Technology Brings Options to Treatment 3Health News:Brain Aneurysm Foundation Provides Key Support to NeuroIntervential Physicians 2Health News:How to Get Toned Arms With Arm Lift Procedure 2Health News:How to Get Toned Arms With Arm Lift Procedure 3Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 2Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 3Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 2Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 3
... , WEDNESDAY, Dec. 8 (HealthDay News) -- ... of developing several invasive bacterial diseases, according to a ... found to be especially strong for children 6 years ... the risk for invasive meningococcal disease, the analysis found, ...
... 8, 2010) Jeffrey S. Upperman, MD, director of ... a call to action for filling a significant gap in ... the framework for a pediatric applied trauma research network (PATRN). ... Journal of Pediatric Surgery and the Journal ...
... breakthrough? See what the experts have to say ... Perspectives on Psychological Science . Neuroimaging: ... Special Section on fMRI ( http://pps.sagepub.com/content/5/6/714.full ) ... widespread interest following the publication of Vul et ...
... , WEDNESDAY, Dec. 8 (HealthDay News) -- The children ... pregnancy are less likely to develop atopic dermatitis in their ... Atopic dermatitis (also called atopic eczema) is a chronic and ... The condition affects up to 20 percent of children in ...
... , WEDNESDAY, Dec. 8 (HealthDay News) -- A new ... blood to scan the genome of a fetus may offer ... genetic diseases, a new study suggests. Currently, a sample ... amniocentesis or chorionic villus sampling, both of which pose a ...
... ANN ARBOR, Mich. Patients who have complications after ... even when it is clearly recommended for their diagnosis, ... Cancer Center finds. In addition, patients with complications ... chemotherapy delayed for more than 120 days after diagnosis ...
Cached Medicine News:Health News:Trauma surgeon leads call to action for pediatric applied trauma research network 2Health News:fMRI special section of Perspectives on Psychological Science 2Health News:fMRI special section of Perspectives on Psychological Science 3Health News:Surgery complications linked to chemotherapy delay, U-M study finds 2
Long-Sleeve Bolero for targeted compression in the upper arms, upper back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
Velcro® closure, uniform contour compression, available as 9" and 12" bands for abdominal support, 9" can be used as a breast wrap....
Sub Pectoral Breast Augmentation Wrap...
CDIs Ultra-Comfort Bra™ is designed with special single needle stitching that places the cup seams away from critical surgical sites....
Medicine Products: